CGTLive’s Weekly Rewind – May 27, 2022


Review top news and interview highlights from the week ending May 27, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Gene Therapy for Knee Cartilage Lesions Receives RMAT Designation

NeoCart was originally developed by the company Histogenics.

2. EtranaDez Accepted for Priority Review in Hemophilia B

A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.

3. Developing Safer Viral Vectors for Gene Therapy

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

4. Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene Therapy in PKD

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.

5. Gene Therapy for AADC Deficiency Receives Positive CHMP Opinion

The positive opinion was based on findings from studies conducted in Taiwan.

Related Videos
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
J. Andrew Livingston, MD
Shankar Musunuri, PhD
Pat Furlong, BSN, RN, on Future Areas of Research in DMD
Michael Kelly, PhD, on Continuing Progress in Muscular Dystrophy in 2024
© 2023 MJH Life Sciences

All rights reserved.